# Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme

> **NCT01866449** · PHASE2 · COMPLETED · sponsor: **University of Ulm** · enrollment: 24 (actual)

## Conditions studied

- Glioblastoma Multiforme (GBM) WHO Grade IV

## Interventions

- **DRUG:** Cabazitaxel

## Key facts

- **NCT ID:** NCT01866449
- **Lead sponsor:** University of Ulm
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2016-12
- **Final completion:** 2017-08-25
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01866449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01866449, "Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT01866449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*